Vaccine/Brand Name Mechs /Name Age Group Recommended &

Doses
Covishield ChAdOx1 nCoV-19 Above 18
(serum institute) Recombinant, replication-deficient 2 doses 12 weeks apart
chimpanzee adenovirus vector
encoding the SARS-CoV-2 Spike (S)
glycoprotein.
Produced in genetically modified
human embryonic kidney (HEK) 293
cells
Covaxin(bharat The vaccine is developed Above 18
biotech) using Whole-Virion Inactivated 2 dose 4 weeks apart
Vero Cell derived platform
technology. Inactivated vaccines do
not replicate and are therefore
unlikely to revert and cause
pathological effects. They contain
dead virus, incapable of infecting
people but still able to instruct the
immune system to mount a
defensive reaction against an
infection.
Sputnik It uses two different human Two doses 21 days apart
Moscow's Gamaleya adenoviruses – Ad26 and Ad5 (out
Institute of the 50 that affect humans) – for
its two vaccine doses

We developed a heterologous
COVID-19 vaccine consisting of two
components, a recombinant
adenovirus type 26 (rAd26) vector
and a recombinant adenovirus type
5 (rAd5) vector, both carrying the
gene for severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-
2) spike glycoprotein (rAd26-S and
rAd5-S)
Pfizer-BioNTech mRNA People 12 years and older
BNT162b2 2 shots
Given 3 weeks (21 days) apart
Moderna mRNA People 18 years and older
mRNA-1273 2 shots
Given 4 weeks (28 days) apart
 APPROVED IN INDIA
Johnson & Johnson’s JNJ-78436735 People 18 years and older
Janssen Viral vector 1 shot
The other candidates which are in different stages of trials in India to test safety and efficacy
include:

ZyCov-Di, being developed by Ahmedabad-based Zydus-Cadila plasmid DNA vaccine

ZyCoV-D is a Plasmid DNA vaccine which when administered produces the spike
protein of the SARS-CoV-2 virus and elicits an immune response mediated by the
cellular and humoral arms of the human immune system, which play a vital role in
protection from disease as well as viral clearance.

Hyderabad-based Biological E to produce the vaccine developed by US firm Johnson & Johnson
HGCO19, India's first mRNA vaccine made by Pune-based Genova in collaboration with
Seattle-based HDT Biotech Corporation, using bits of genetic code to cause an immune
response